title: Comparative efficacy of acid reflux inhibition by drug therapy in reflux esophagitis.
abstract: The advent of histamine H2 receptor antagonists (H2-RA) has allowed the treatment of reflux esophagitis (RE) to be controlled over a relatively long term. The authors have experienced some cases resistant to H2-RA, but it was revealed that these cases can be successfully treated with proton pump inhibitors. It has been suggested that esophagogastric dysmotility can lead to RE. RE has been treated for many years by using GI-prokinetic agents, which theoretically inhibit acid reflux and improve esophageal acid clearance. In order to compare the effects on acid reflux of an H2-RA (famotidine), a proton pump inhibitor (omeprazole) and a GI-prokinetic agent (cisapride), we measured the 24-hour pH in the esophagus and stomach simultaneously, before and after treatment in 17 patients with RE. It was found that the proton pump inhibitor was the most effective drug for inhibiting esophageal acidification, followed by famotidine and then cisapride. Furthermore, we found that cisapride often actually exacerbated acid reflux. The differences in inhibitory effects on acidification allowed us to draw conclusions regarding the treatment of RE. It was concluded that the stronger the inhibitory effect of a drug on acid secretion, the more useful it was in the treatment of RE. The GI-prokinetic drug did not inhibit acid reflux as much as we had expected.
authors.affiliation: First Department of Internal Medicine, Gunma University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sekiguchi
authors.forename: T
authors.initials: T
authors.lastname: Nishioka
authors.forename: T
authors.initials: T
authors.lastname: Matsuzaki
authors.forename: M
authors.initials: M
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Kusano
authors.forename: T
authors.initials: T
authors.lastname: Horikoshi
authors.forename: M
authors.initials: M
authors.lastname: Toki
authors.forename: T
authors.initials: T
authors.lastname: Ohwada
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D020117:Cisapride; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004947:Esophagus / Q000503:physiopathology; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008991:Monitoring, Physiologic; D009853:Omeprazole / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013270:Stomach / Q000503:physiopathology
chemical_list: D010880:Piperidines; D012702:Serotonin Antagonists; D015738:Famotidine; D009853:Omeprazole; D020117:Cisapride